Skip to content

Depression: all studies

Page 828 of 1,034: studies 8,271 to 8,280 of 10,336, newest first. Back to the depression overview

Research

Psilocybin: from ancient magic to modern medicine

The Journal of Antibiotics May 12, 2020 David E. Nichols 184 citations

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. South American Aztec Indians referred to them as teonanacatl, meaning "god's flesh," and they were used in religious and healing rituals. Spanish missionaries in the 1500s attempted to destroy all records and evidence of the use of these mushrooms. Nevertheless,...

DOI: 10.1038/s41429-020-0311-8 (opens in new tab) Psilocybin Magic telescope Hallucinogen Traditional medicine +2

Can Psychedelics Alleviate Symptoms of Cluster Headache and Accompanying Mental Health Problems? A Case Report Involving Hawaiian Baby Woodrose

Journal of Psychoactive Drugs May 7, 2020 Shevaugn Johnson, Q. C. Black

ABSTRACT Preliminary evidence supports the efficacy of psychedelics in the alleviation of cluster headache and mental health problems. We describe a case of an individual with cluster headache and mood disorder who claims to have benefited from her use of psychedelics. A forty-eight-year-old woman was referred to a private Australian mental health clinic for the management of chronic pain and...

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials

The International Journal of Neuropsychopharmacology May 5, 2020 Ziad S. Saad, D. Hibar, Maggie Fedgchin et al. 43 citations

Abstract Background At ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist effects. Preliminary clinical studies showed conflicting results on whether naltrexone, a...

Loving-Kindness Meditation Promotes Mental Health in University Students

Mindfulness May 2, 2020 Christina Totzeck, Tobias Teismann, Stefan G Hofmann et al. 62 citations

Abstract Objectives Loving-kindness meditation (LKM) has been shown to improve wellbeing and positive emotions in clinical and non-clinical populations. The main goal of the present study was to examine whether LKM might be an effective intervention to promote positive mental health using the Positive Mental Health Scale (PMH) and to decrease depression, anxiety, and stress in university...

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.

Psychopharmacology May 1, 2020 Toby Lea, Nicole Amada, Henrik Jungaberle et al.

The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. This paper examined subjective experiences of microdosing...

The Effects of Mantra Meditation on Self-compassion and Stress of Office Workers

Asia-pacific Journal of Convergent Research Interchange April 30, 2020 Hee-sook Kwon, Mee-sook Cheong

High job-stress is more than 2 times likely to cause depression, anxiety, and stress symptoms. More 70% of professional managers responded that they felt stressed in their workplaces for the past 10 years. This study investigates the effects of mantra meditation on self-compassion and stress of office workers. The subjects of this study were 20 head managers of apartments in K city. The purpose...

Ayahuasca – potential therapeutic properties in psychiatry. Research review

Psychiatria Polska April 30, 2020 Aleksandra Barabasz-Gembczyk, Krzysztof Kucia 4 citations

Ayahuaska, zwana również „lianą duszy”, „pnączem duszy” to rytualny psychodelik podawany tradycyjnie w formie wywaru roślinnego, od stuleci stosowany przez rdzenną ludność Ameryki Południowej, a w ostatnich 25 latach również w krajach Europy, Azji, Afryki, Australii, w Kanadzie i Stanach Zjednoczonych Ameryki Północnej. Jej aktywność biologiczna wynika z zawartości N,N- dimetrylotryptaminy...

Shocking colours - ECT temporarily improves colour perception in a colour-blind patient

Brain Stimulation April 28, 2020 Kristian H. R. Jensen, Sofie Trolle Pedersen, Mette Vinther Hansen et al. 2 citations

Electroconvulsive therapy (ECT) is often the last resort in medically treatment-resistant patients. The mechanisms of its efficacy are still somewhat poorly understood. However, it is clearly a highly effective treatment for severe and psychotic depression, as well as other severe neuropsychiatric conditions [1]. This case-report attempts to offer a perspective on the impact of ECT on sensorial...

DOI: 10.1016/j.brs.2020.04.018 (opens in new tab) Olanzapine Depression economics Schizophrenia object-oriented programming Electroconvulsive therapy studies

Mindfulness-based Stress Reduction on Unhealthy Emotions and Sleep Quality of Hematopoietic Stem Cell Transplantation Recipients

Advanced Biomedicine April 25, 2020 Wu Xiafen, Huang Guohua, Wang Chunli et al.

Objective: We attempt to explore the effect of mindfulness-based stress reduction on unhealthy emotion and sleep quality of hematopoietic stem cell transplantation recipients. Methods: we enrolled 92 patients who underwent hematopoietic stem cell transplantation recipients in the Hematology Department of our hospital from February 2017 to August 2019 and averagely divided them into control...

R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder.

Pharmacology, Biochemistry, and Behavior April 22, 2020 Jeffrey M. Witkin, J. Kranzler, K. Kaniecki et al. 33 citations

Substance abuse disorder continues to have devastating consequences for individuals and society and current therapies are not sufficient to provide the magnitude of medical impact required. Although some evidence suggests the use of ketamine in treating various substance use related- symptoms, its adverse event profile including dissociation, dysphoria, and abuse liability limit its potential...